Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Certolizumab pegol

Nature Reviews Drug Discovery volume 7, pages 641–642 (2008)Cite this article

Abstract

Credit: Certolizumab pegol

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Characteristics of tumour-necrosis factor blockers.

References

  1. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nature Rev. Immunol. 3, 521–533 (2003).

    Article  CAS  Google Scholar 

  2. Korzenik, J. R. & Podolsky, D. K. Evolving knowledge and therapy of inflammatory bowel disease. Nature Rev. Drug Discov. 5, 197–209 (2006).

    Article  CAS  Google Scholar 

  3. Loftus, E. V. Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504–1517 (2004).

    Article  Google Scholar 

  4. Targan, S. R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J Med. 337, 1029–1035 (1997).

    Article  CAS  Google Scholar 

  5. Chang, J. T. & Lichtenstein, G. R. Drug insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nature Clin. Pract. Gastroenterol. Hepatol. 3, 220–228 (2006).

    Article  CAS  Google Scholar 

  6. Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).

  7. Nesbitt, A. et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis. 13, 1323–1332 (2007).

    Article  Google Scholar 

  8. Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 228–238 (2007).

    Article  CAS  Google Scholar 

  9. Schreiber, S. et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007).

    Article  CAS  Google Scholar 

  10. Peyrin-Biroulet, L. et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6, 644–653 (2008).

    Article  CAS  Google Scholar 

  11. Sandborn, W. J. et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146, 829–838 (2007).

    Article  Google Scholar 

  12. Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52–65 (2007).

    Article  CAS  Google Scholar 

  13. D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).

    Article  CAS  Google Scholar 

  14. IMS Health Analysis, IMS MIDAS Quantum, MAT (2007).

Download references

Author information

Authors and Affiliations

  1. Gil. Y. Melmed and Stephan R. Targan are at the Cedars-Sinai Inflammatory Bowel Disease Center, UCLA School of Medicine, Los Angeles, California 90048, USA. targans@cshs.org,

    Gil Y. Melmed & Stephan R. Targan

  2. Uma Yasothan and Delphine Hanicq are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan & Delphine Hanicq

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Gil Y. Melmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephan R. Targan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Delphine Hanicq
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

G.Y.M. is on a speaker's bureau for Abbott, Shire and Procter & Gamble, receives research funding from Centocor, and serves on the advisory board for Elan. S.R.T is a consultant to Elan and Centocor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melmed, G., Targan, S., Yasothan, U. et al. Certolizumab pegol. Nat Rev Drug Discov 7, 641–642 (2008). https://doi.org/10.1038/nrd2654

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2654

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing